Forepont Capital Partners deploy long-term capital to fuel growth of new medicines and technologies that drive better healthcare outcomes. Our strategic partnership with Freyeur & Trogue brings a unique combination of experience, expertise and banking know how.
Forepont Capital Partners and Freyeur & Trogue come together to create a powerhouse in life-science investing. The team has an outstanding track record of high growth exits and return to investors.
Freyeur & Trogue is a Specialty Investment Bank with a focus on high growth strategies in the pharma/biotech and life science sectors. Freyeur & Trogue brings deep sector experience, a unique range of complimentary skill-sets: investment banking, business development and commercial strategy and a team that has over $100 billion in deal experience.
Genomics, imaging, and biomarkers that translate into the development and use of systems therapeutics. Systems Therapeutics - medicines that target specific pathways to modify the course of disease and are intended for personalized or stratified use in specific patient populations to drive better outcomes along with reduced adverse effects. The right drug for the right disease in the right patient.
Data, wearables, mobile apps and other technologies that enable more rapid changes to treatment protocols, increasing patient engagement and accountability, shifting patient-provider interaction, and accelerating the adoption of behavior changes that will improve patient adherence to treatments, manage their condition and adapt lifestyle to enable better healthcare outcomes at lower costs.